Hyperphenylalaninaemia (HPA) is an inherited disorder that results in raised plasma phenylalanine levels with a range of severities, including phenylketonuria (PKU). Since the first attempts at treatment using a low-phenylalanine diet and after more than 50 years of research, considerable progress has been made so we are now at a stage where mental retardation caused by high plasma phenylalanine can be prevented. We must, however, be aware of the new challenges we face in managing PKU. These include: maintaining optimal growth by providing enough phenylalanine without jeopardizing the child's psychomotor development; providing an optimal nutritional status that ensures other essential nutrients, such as long chain polyunsaturated fatty acids, are not excluded from the diet; ensuring optimal compliance to the dietary intervention; and considering patients' quality of life. New strategies, such as tetrahydrobiopterin (BH4) supplementation, need to be evaluated with regard to safety, efficacy and expected outcomes in specific types of HPA.
Introduction
Hyperphenylalaninaemia (HPA) is a disorder caused by a deficiency in phenylalanine hydroxylase (PAH; McKusick 261600), which converts dietary phenylalanine (Phe) to tyrosine (Tyr). 1 The range of disease severity observed among patients with HPA is primarily due to allelic heterogeneity at the PAH locus. Various combinations of mutations result in a full spectrum of metabolic phenotypes ranging from severe, moderate and mild phenylketonuria (PKU; blood Phe levels > 360 mmol/l), which require dietary management, to mild HPA (blood Phe levels 120 -360 mmol/l), for which dietary restriction is not necessary. 2 Small numbers of cases of HPA are due to a mutation of one of the enzymes involved in the synthesis or recycling of the cofactor, tetrahydrobiopterin (BH4), 1 which is involved in the oxidation of Phe.
In children with PKU, severe neurological and functional disorders can be prevented by the early introduction of a strict dietary regimen aimed at reducing blood Phe concentrations to non-toxic levels (120 -360 mmol/l). 1 However, structural changes in the brain 3 and abnormalities of visual function 4 have still been shown to occur even in well-M Giovannini, E Riva, E Salvatici et al. Treating phenylketonuria in children managed children with HPA, which has raised questions about the adequacy of the dietary intervention. 5
Dietary treatment for PKU
The main goal of PKU treatment is to maintain blood Phe levels within safe limits (120 -360 mmol/l normally; 120 -240 mmol/l for pregnant women) in order to prevent mental retardation, ensure normal growth and a normal life with good health throughout adulthood. This can be done by the introduction of a low Phe diet. When dietary intervention is started in the neonatal period it modifies the metabolic phenotype and prevents the neuropsychological consequences of HPA. 1 Indeed, high blood Phe levels are neurotoxic, mainly because of their inhibitory effect on the transport of free L-amino acids (leucine, isoleucine, valine, tyrosine, tryptophan and lysine) which are necessary for the synthesis of proteins and neurotransmitters (dopamine and serotonin). 1 The diet normally used to treat PKU patients is semi-synthetic and, although low in Phe, it is adequate in other nutrients. It consists mainly of fruit and vegetables (low in Phe) and synthetic products that provide appropriate amounts of essential amino acids. The diet uses minimal amounts of animal products (generally milk), to provide enough Phe for growth processes.
Evidence of structural alterations in brain tissue 3 and anomalies in visual function, as evaluated by visual evoked potentials (VEP), 4 which have been observed in well-nourished PKU children who have demonstrated optimal compliance to the dietary intervention, has raised questions concerning the efficacy of this treatment. In fact, it has been observed that this type of diet may result in nutritional deficits, 6 which then have consequences for growth and development of the child. Studies have highlighted an inadequate intake of taurine, 7 carnitine 8 and other micronutrients, which are mainly available in the animal products that are not permitted in the dietary intervention for PKU patients. In particular, PKU patients are recommended to have a low intake of long chain polyunsaturated fatty acids (LC-PUFAs), such as arachidonic acid (AA) and docosahexaenoic acid (DHA), which are only found in animal products. 9 PKU patients, therefore, have to rely on the endogenous synthesis of LC-PUFAs from their precursor molecules, which might also be at suboptimal concentrations in their diet, particularly so for α-linolenic acid (ALA), the precursor of DHA. The successful dietary treatment of PKU may, therefore, result in an iatrogenic decrease of the circulating DHA pools.
The single centre Italian experience
We present the data from our patients with HPA that were diagnosed and followed-up by the Department of Paediatrics, San Paolo Hospital, University of Milan, Milan, Italy, from 1960 to 2006. Neonatal screening for HPA has been compulsory by law in Italy since 5 February 1992, but has been undertaken in the Lombardy region since 1 January 1977. Every newborn baby is, therefore, screened for HPA and, if they test positive, they are sent to our centre for diagnosis confirmation. Routine diagnostic investigations consist of a general clinical evaluation and quantitative measurement of plasma amino acid levels. A BH4 loading test, analysis of urinary proteins and determination of dihydropteridine reductase activity in blood are performed to exclude BH4 deficiency.
As of 1 September 2006, a total of 537 patients had been diagnosed with HPA by M Giovannini, E Riva, E Salvatici et al. Treating phenylketonuria in children the Department of Paediatrics. We actively followed-up 445 of these: 240 (54%) were males and 205 (46%) were females. Their mean age was 15 years and 6 months (range, 3 months -46 years). With regard to their nationalities, 94.8% were European, 2.8% Asian, 1.9% African and 0.5% were South American.
NEONATAL PERIOD
Of the 445 patients that were followed-up, 415 were children for whom we had detailed information on their birth status, and showed a mean gestational age of 39.3 weeks. A total of 22 children (5.3%) were born pre-term (< 37 weeks), 392 (94.4%) were born at term (37 -42 weeks), and one child (0.2%) was born post-term (> 42 weeks). Anamnestic data was available from 411 children, which showed 241 children (58.6%) were exclusively breast-fed before diagnosis, 114 (27.7%) were formula-fed, and 56 (13.6%) received complementary feeding with both breast milk and infant formula.
Analysis of the anthropometric birth measurements was undertaken for 237 children and the mean birth weight was 3274 g (females, 3211 g; males, 3330 g). Of these, 219 (92.4%) had a normal birth weight (2500 -4000 g), 10 (4.2%) had a low birth weight (< 2500 g) and eight (3.4%) were large for their gestational age (> 4000 g). The mean body length was 49.5 cm (females, 49.2 cm; males, 49.8 cm) and the mean head circumference was 34.2 cm (females, 33.9 cm; males, 34.5 cm).
A diagnosis of HPA was made within the first month of life in 92.3% of the cases actively followed up (n = 445). The mean of three Guthrie tests carried out 3 days after birth to test for increased plasma Phe levels was 546 mmol/l (range, 120 -3600 mmol/l 
METABOLIC COMPLIANCE
Dietary data were available for 436 patients: 217 (49.8%) patients with PKU followed a low Phe diet; and 219 (50.2%) with mild HPA were able to have an unrestricted diet. The main goal of the dietary treatment for those patients with PKU was to maintain their plasma Phe levels within the safe limits of 120 -360 mmol/l. Table 1 shows plasma Phe levels in the two groups of children from birth to 12 years of age. At each age, the plasma Phe levels of the children with PKU on the low Phe diet decreased significantly (P < 0.0001) compared with at birth once the dietary intervention had been introduced, demonstrating the efficacy of the strict dietary regimen in maintaining good metabolic control. During the first year of life, the mean plasma Phe level was measured weekly in each child. The mean value for both groups of children (n = 436) was 342 mmol/l, which indicates relatively good metabolic compliance. By the age of 5 years, the mean plasma Phe level was 470.5 mmol/l in children who received the dietary intervention compared with 261.7 mmol/l in those on an unrestricted diet. By 12 years of age, the beginning of adolescence, the mean plasma Phe level was indicative of a fair degree of metabolic control, being 678.4 mmol/l in children on the dietary intervention and 361.6 mmol/l in children on an unrestricted diet.
M Giovannini, E Riva, E Salvatici et al. Treating phenylketonuria in children ANTHROPOMETRIC MEASUREMENTS
Anthropometric measurements of the children with PKU were obtained at birth and 1, 3, 5, 8 and 12 years of age. The zscores for weight, height and body mass index (BMI) were calculated for each age and compared between the children on dietary intervention and those on an unrestricted diet using a two-way analysis of variance (ANOVA) (Tables 2 -4). Our findings demonstrate that there was no significant difference between the two groups in the growth parameters at birth. The mean z-scores for weight and height improved in the children diagnosed with PKU after dietary intervention commenced, which was usually around 3 weeks of age in newborns screened for HPA at birth. The mean z-scores for weight and height were significantly lower in the children with PKU undergoing dietary management than in the children on an unrestricted diet between 1 and 12 years of age (Tables 2 and 3 ). The mean z-scores for BMI showed no statistically differences between the two groups from birth to the age of 12 years (Table 4) .
Poor growth has been attributed to excessive Phe restriction, and severe growth retardation in children given initial diets that are extremely restrictive in Phe suggests that appropriate Phe intake is absolutely necessary to ensure optimal growth. 1 (Table 5 ). No significant difference in psychomotor development was found between the intelligence quotients (IQs) of the two groups at 1 year of age, suggesting that the children with PKU on the dietary intervention had a mental and motor development that was comparable with the children with mild HPA. This observation underlines the importance of early introduction of a low Phe diet in preventing mental retardation.
PSYCHOMOTOR DEVELOPMENT
We also evaluated the IQs of 95 children between 3 and 6 years of age using the McCarthy scale or the Wechsler Preschool and Primary Scale of Intelligence (WPPSI). The mean (±SD) score for the overall population (n = 95) was 106.7 ± 11.8. Of these, 62 children were on the dietary intervention and their mean (±SD) IQ score was 105.9 ± 12.6; for the 33 children on an unrestricted diet it was 108.6 ± 10.9. These results were not significantly different between the two groups.
We also evaluated the IQs in 151 children between 6 and 16 years of age using the revised Wechsler Intelligence Scale for Children (WISC-R) development scale. The mean (±SD) IQ score for the overall population (n = 151) was 102.9 ± 10.8. Of these, 112 children were on the dietary intervention and their mean (±SD) IQ score was 100.4 ± 11.4; the 39 children on an unrestricted diet had a mean (±SD) IQ score of 110.1 ± 10.5. When this group of 151 children were analysed according to those screened at birth for HPA (n = 137) the mean (±SD) IQ score was 106.7 ± 16.7. This compared with a mean (±SD) IQ score of 65. The children that were diagnosed early through neonatal screening and who underwent early dietary intervention had a significantly higher mean WISC-R IQ score between 6 and 16 years of age than those children diagnosed later (P < 0.0001). Finally, we measured the IQ using the Wechsler Adult Intelligence Scale (WAIS) of 70 children ≥16 years age, which showed a mean (±SD) IQ score for the overall population of 94.2 ± 9.2. Of these, 60 children were on the dietary intervention and their mean (±SD) IQ score was 93.8; the 10 children on an unrestricted diet had a mean (±SD) IQ score of 96.5 ± 8.7. There was no significant difference between these two groups. When this group of children was analysed according to HPA screening at birth and, therefore, for early or late diagnosis, the 47 children that were diagnosed at birth had a significantly higher mean (±SD) WAIS IQ score of 105.2 ± 11.5 compared with the 23 children that were diagnosed at a later stage (WAIS IQ score of 71.8 ± 17.5; P < 0.0001).
When we analysed the IQs based on the type of feeding the children had received before diagnosis of HPA, we found that the mean MDI IQ score at 1 year of age was higher (not statistically significant), in those who had been breast-fed (96.2) than in those fed infant formula (91.8). A similar result was found for the PDI IQs, with breast-fed children having a mean score of 99.5 compared with infant formula-fed infants who had a mean score of 98.0 at 1 year of age and similar trends were seen with all of the other IQ tests: McCarthy or WPPSI scales IQ breast-fed 107.6 versus infant formula-fed 101.8; WISC-R IQ breast-fed 102.3 versus infant formula-fed 100.9; and WAIS IQ breast-fed 99.9 versus infant formula-fed 92.0 (all not statistically significant).
PKU: nutritional challenges performed in our centre

BREAST MILK AND BREAST FEEDING
The neurodevelopment of early-treated patients with PKU has been found to be poorer than the general population. 10 It has previously been shown that the age at which dietary intervention is started clearly influences patient outcome, 11 with an inverse relationship having been shown between the age of starting dietary therapy and IQ, even in early-treated PKU subjects. The type of feeding received by the newborn before the diagnosis of HPA also plays a fundamental role. In an earlier study, we demonstrated the beneficial effect of breast feeding on behavioural development, even when practised for only a short period (20 -40 days), in term newborns with classical PKU. 12 Several factors linked with the composition of breast milk might account for this benefit, for example its lower Phe content compared with standard infant formulas, 13 its optimal Phe/tyrosine ratio, and the presence of LC-PUFAs, particularly AA and DHA, which positively influence growth and functional development of the brain. 14 It is, therefore, very important to encourage the mothers of children with PKU to breast feed, particularly when one considers the low breast feeding rates found in the PKU population. 15 After a diagnosis of PKU, mothers need psychological and technical support to maintain breast feeding so that the infant can benefit from the expected advantages for disease outcome and to help develop the mother-infant relationship.
LC-PUFAs in infancy and childhood
The first few months of life are the most vulnerable for brain development, so early supplementation with preformed LC-PUFAs could be an important addition to the nutrition of infants with PKU. Early breast feeding appears to be associated with a better developmental outcome for older children with PKU 12 and, as human milk is a rich source of preformed LC-PUFA, it is tempting to suggest that this is the reason. 16 Infancy is the most critical post-partum stage for neurological development. The striking variations that have been found in the DHA content of the prefrontal brain cortex in breast-fed compared with formula-fed infants provide convincing evidence of the effects of a dietary supply of LC-PUFA on brain structure. 17, 18 Subtle neurological deficits have been observed in later life in dietary-treated PKU patients, 10 and some have speculated that this may be a consequence of a poor intake of LC-PUFAs during infancy. 19 The effects of LC-PUFA supplementation in infants with PKU have been investigated in a randomized, controlled trial. 20 This showed that a dietary supply of LC-PUFA in infants with PKU prevented the decline in DHA status that is associated with a diet supplying minimal sources of LC-PUFA. It has also been demonstrated that DHA status, irrespective of any specific supplementation, is associated with earlier visual signs of maturation in infants with PKU, to be comparable with those seen in healthy infants. 21 Using a Phe-free infant formula supplemented with LC-PUFAs might minimize the risk of infants with PKU having a sub-optimal DHA status.
In our studies we found that children with PKU have a poor LC-PUFA status. 22 We showed that the addition of DHA and AA to the diets of older children with PKU raised the plasma levels of these fatty acids and improved the treated children's visual response. 22, 23 However, 3 years after supplementation we found no biochemical or functional differences between supplemented and non-supplemented children. 23 
Quality of growth: prevention of later excessive weight gain
Studies have shown that children with PKU tend to weigh more than normal children. 24 -26 We found that around 25% of our 8-year old children with PKU were overweight, which is a value that is comparable with estimates for the general M Giovannini, E Riva, E Salvatici et al. Treating phenylketonuria in children population. 26 We also found no difference between children with PKU and those with mild HPA. Our previous study revealed a strong negative association between being overweight at 8 years of age and the age when BMI rebounds (the age at which the BMI reaches nadir and starts to increase); 27 the BMI rebound age has been proposed to predict the occurrence of obesity in adulthood in normal populations. 27 Even if PKU children are routinely monitored for their dietary intake in the long term there is, therefore, evidence that they may still become overweight.
New strategies studied in our centre
Competing amino acids. The role of large neutral amino acids (LNAAs) and their transport to the brain in PKU has been the subject of research since 1953 when Christensen 28 proposed that a high level of Phe in the blood interfered with the transport of other LNAAs into the brain and Pietz et al. 29 demonstrated, by giving an oral Phe challenge with and without LNAAs, that LNAAs blocked the transport of Phe into the brain. In view of the fact that many adults and adolescents with PKU are either not on a low Phe diet or do not adhere to one, it would seem prudent to offer them LNAA therapy. The use of LNAA therapy has been shown to improve amino acid profiles, in particular to increase tyrosine and tryptophan concentrations in the blood, which are the precursors for dopamine and serotonin. 30
BH4 supplementation in BH4-responsive HPA patients. Patients affected by BH4 deficiency show normalization of plasma
Phe levels after oral administration of BH4. 1 Recently, patients affected by PAH deficiency have also been shown to respond to the oral administration of BH4, as demonstrated by reduced plasma Phe levels. 31 Most BH4-responsive patients are affected by mild HPA, however a smaller number show more severe phenotypes with low Phe tolerance and undergo dietary intervention. In the latter group, BH4 may represent a valid alternative to standard dietary treatment. 31 BH4 therapy may be important for these patients, especially during adolescence when compliance to a low Phe diet can be poor, and during pregnancy in order to improve Phe control. 32 In a recent study, we determined the incidence of BH4 responsiveness in a non-selected cohort of HPA patients and verified the genotype-phenotype correlation in BH4-responsiveness. 33 The total incidence of BH4-responsiveness in our cohort was 85% and BH4 significantly lowered blood Phe levels in 91 (85%) of 107 patients affected by PAH-deficient HPA. Most of the responsive patients were affected by mild HPA (77%), 7% had mild PKU and 7% had moderate PKU. One patient with severe PKU was responsive to BH4. A total of 18 mutations were found to be associated with the BH4responsive phenotype but the genotype did not appear to be the only factor determining BH4-responsiveness. 33 
Conclusion
In conclusion, BH4 could be either a good alternative to dietary intervention or a useful additional therapy in different forms of HPA with varying degrees of PAH residual enzyme activity. Multicentre standardized studies are necessary to assess the responsiveness to BH4 in HPA patients in order to define the safety and efficacy of this therapy and define guidelines for treatment.
Since the first attempts to treat PKU using a low-Phe diet and, after more than 50 years of research, considerable progress has been made. We must, however, be aware of the new challenges we face in managing PKU. These include: maintaining optimal growth; trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria. providing an optimal nutritional status for other essential nutrients, such as LC-PUFAs; ensuring optimal compliance to the dietary intervention; and considering patients' quality of life. New strategies, such as BH4 supplementation, need to be evaluated with regard to safety, efficacy and expected outcomes in specific types of HPA.
Conflicts of interest
No conflicts of interest were declared in relation to this paper.
